379 related articles for article (PubMed ID: 16388858)
21. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
22. Granulocyte/macrophage colony-stimulating factor and interleukin-4-induced dendritic cells.
Hikino H; Kasono K; Kanzaki M; Kai T; Konishi F; Kawakami M
Anticancer Res; 2004; 24(3a):1609-15. PubMed ID: 15274330
[TBL] [Abstract][Full Text] [Related]
23. CD40 engagement strongly induces CD25 expression on porcine dendritic cells and polarizes the T cell immune response toward Th1.
Pilon C; Levast B; Meurens F; Le Vern Y; Kerboeuf D; Salmon H; Velge-Roussel F; Lebranchu Y; Baron C
Mol Immunol; 2009 Jan; 46(3):437-47. PubMed ID: 19036453
[TBL] [Abstract][Full Text] [Related]
24. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
25. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
[TBL] [Abstract][Full Text] [Related]
26. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
27. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
[TBL] [Abstract][Full Text] [Related]
28. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction.
Bellinghausen I; König B; Böttcher I; Knop J; Saloga J
Clin Exp Allergy; 2006 Dec; 36(12):1546-55. PubMed ID: 17177678
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
31. [Induction of Th1 immune response against tumor by genetically engineered fusion of tumor cells and dendritic cells].
Zhang W; Yang H; Zeng H; Chen Z
Zhonghua Xue Ye Xue Za Zhi; 2002 Feb; 23(2):61-4. PubMed ID: 12015071
[TBL] [Abstract][Full Text] [Related]
32. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
Liu Z; Fan H; Wu Y; Chen B
Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
[TBL] [Abstract][Full Text] [Related]
33. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
[TBL] [Abstract][Full Text] [Related]
34. The ability of murine dendritic cell subsets to direct T helper cell differentiation is dependent on microbial signals.
Manickasingham SP; Edwards AD; Schulz O; Reis e Sousa C
Eur J Immunol; 2003 Jan; 33(1):101-7. PubMed ID: 12594838
[TBL] [Abstract][Full Text] [Related]
35. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma.
Pajtasz-Piasecka E; Rossowska J; Duś D; Weber-Dabrowska B; Zabłocka A; Górski A
Immunol Lett; 2008 Feb; 116(1):24-32. PubMed ID: 18166233
[TBL] [Abstract][Full Text] [Related]
36. Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.
Pajtasz-Piasecka E; Rossowska J; Szyda A; Krawczenko A; Dus D
Oncol Rep; 2007 May; 17(5):1249-57. PubMed ID: 17390073
[TBL] [Abstract][Full Text] [Related]
37. Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells.
Liu KJ; Lu LF; Cheng HT; Hung YM; Shiou SR; Whang-Peng J; Juang SH
Cancer Gene Ther; 2004 Feb; 11(2):135-47. PubMed ID: 14647233
[TBL] [Abstract][Full Text] [Related]
38. Glycogen synthase kinase 3 activity during development of bone marrow-derived dendritic cells (DCs) essential for the DC function to induce T helper 2 polarization.
Ono T; Yanagawa Y; Iwabuchi K; Nonomura K; Onoé K
Immunology; 2007 Oct; 122(2):189-98. PubMed ID: 17490435
[TBL] [Abstract][Full Text] [Related]
39. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
[TBL] [Abstract][Full Text] [Related]
40. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
